…
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
iShares Global Healthcare ETF offers diversified exposure to global healthcare companies across pharmaceuticals, biotechnology, medical devices and healthcare services. Long-term growth drivers include aging populations, rising healthcare spending and ongoing medical-technology and drug innovation, which could support demand for sector revenues. The fund may appeal to investors seeking targeted healthcare exposure with lower cyclicality than some equity sectors.
Key risks include sector concentration leading to higher volatility, regulatory and clinical-trial outcomes affecting company revenues, and currency and market fluctuations that can impact returns.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| IXJ Ishares Global Healthcare ETF |
1.95 1.18% |
166.80 | - | - | - | - |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.